Barchart.com
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Marriot Vacations Worldwide Cor (VAC)

Marriot Vacations Worldwide Cor (VAC)
52.36 -0.44 (-0.83%) 10:32 ET [NYSE]
52.29 x 4 52.69 x 100
Realtime by (Cboe BZX)
52.29 x 4 52.69 x 100
Realtime 53.56 +0.76 (+1.44%) 04:24 ET
Quote Overview for Tue, Apr 22nd, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Day Low
52.57
Day High
53.94
Open 53.63
Previous Close 52.80 52.80
Volume 46,172 46,172
Avg Vol 557,275 557,275
Stochastic %K 22.50% 22.50%
Weighted Alpha -52.85 -52.85
5-Day Change -1.00 (-1.86%) -1.00 (-1.86%)
52-Week Range 49.22 - 103.51 49.22 - 103.51
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
 Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,824,926
  • Shares Outstanding, K 34,563
  • Annual Sales, $ 4,967 M
  • Annual Income, $ 218,000 K
  • EBIT $ 636 M
  • EBITDA $ 808 M
  • 60-Month Beta 1.66
  • Price/Sales 0.37
  • Price/Cash Flow 4.32
  • Price/Book 0.76

Options Overview Details

View History
  • Implied Volatility 70.07% ( +3.52%)
  • Historical Volatility 77.60%
  • IV Percentile 98%
  • IV Rank 77.86%
  • IV High 81.85% on 04/08/25
  • IV Low 28.63% on 05/20/24
  • Put/Call Vol Ratio 5.81
  • Today's Volume 218
  • Volume Avg (30-Day) 135
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 2,494
  • Open Int (30-Day) 6,570

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.59
  • Number of Estimates 7
  • High Estimate 1.90
  • Low Estimate 1.29
  • Prior Year 1.80
  • Growth Rate Est. (year over year) -11.67%
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.
Get delivered to your inbox for FREE:
Sign Up.

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.22 +7.46%
on 04/09/25
Period Open: 65.85
68.74 -23.06%
on 03/25/25
-12.96 (-19.68%)
since 03/21/25
3-Month
49.22 +7.46%
on 04/09/25
Period Open: 86.11
91.18 -41.99%
on 02/19/25
-33.22 (-38.58%)
since 01/22/25
52-Week
49.22 +7.46%
on 04/09/25
Period Open: 98.89
103.51 -48.90%
on 04/26/24
-46.00 (-46.52%)
since 04/22/24

Most Recent Stories

More News
VAC
Marriott Vacations (VAC): Buy, Sell, or Hold Post Q4 Earnings? StockStory - Fri Apr 18, 4:14AM CDT

Marriott Vacations (VAC): Buy, Sell, or Hold Post Q4 Earnings?

YUM : 143.02 (+1.79%)
VAC : 52.36 (-0.83%)
VAC
Q4 Earnings Highs And Lows: Marriott Vacations (NYSE:VAC) Vs The Rest Of The Travel and Vacation Providers Stocks StockStory - Mon Apr 7, 4:06AM CDT

Q4 Earnings Highs And Lows: Marriott Vacations (NYSE:VAC) Vs The Rest Of The Travel and Vacation Providers Stocks

PRSU : 29.33 (+1.10%)
H : 104.89 (+0.64%)
SABR : 2.03 (+1.00%)
VAC : 52.36 (-0.83%)
CCL : 17.53 (+1.68%)
VAC
Marriott Vacations (VAC) Stock Trades Down, Here Is Why StockStory - Thu Apr 3, 2:59PM CDT

Marriott Vacations (VAC) Stock Trades Down, Here Is Why

VAC : 52.36 (-0.83%)
TH
Reflecting On Travel and Vacation Providers Stocks’ Q4 Earnings: Target Hospitality (NASDAQ:TH) StockStory - Tue Apr 1, 4:13AM CDT

Reflecting On Travel and Vacation Providers Stocks’ Q4 Earnings: Target Hospitality (NASDAQ:TH)

PRSU : 29.33 (+1.10%)
CHH : 120.55 (-0.21%)
TH : 6.42 (+1.10%)
H : 104.89 (+0.64%)
VAC : 52.36 (-0.83%)
AAL
Travel and Vacation Providers Stocks Q4 Results: Benchmarking American Airlines (NASDAQ:AAL) StockStory - Wed Mar 19, 4:02AM CDT

Travel and Vacation Providers Stocks Q4 Results: Benchmarking American Airlines (NASDAQ:AAL)

LIND : 8.23 (+1.86%)
PRSU : 29.33 (+1.10%)
H : 104.89 (+0.64%)
VAC : 52.36 (-0.83%)
AAL : 9.07 (-0.03%)
TNL
Q4 Earnings Outperformers: Travel + Leisure (NYSE:TNL) And The Rest Of The Travel and Vacation Providers Stocks StockStory - Fri Mar 14, 4:08AM CDT

Q4 Earnings Outperformers: Travel + Leisure (NYSE:TNL) And The Rest Of The Travel and Vacation Providers Stocks

PRSU : 29.33 (+1.10%)
TNL : 41.45 (+1.54%)
H : 104.89 (+0.64%)
VAC : 52.36 (-0.83%)
CCL : 17.53 (+1.68%)
CCL
Reflecting On Travel and Vacation Providers Stocks’ Q4 Earnings: Carnival (NYSE:CCL) StockStory - Thu Mar 13, 4:09AM CDT

Reflecting On Travel and Vacation Providers Stocks’ Q4 Earnings: Carnival (NYSE:CCL)

PRSU : 29.33 (+1.10%)
NCLH : 16.34 (+1.81%)
H : 104.89 (+0.64%)
VAC : 52.36 (-0.83%)
CCL : 17.53 (+1.68%)
Marriott Vacations Worldwide: Q4 Earnings Snapshot AP - Wed Feb 26, 5:24PM CST

Marriott Vacations Worldwide: Q4 Earnings Snapshot

VAC : 52.36 (-0.83%)
VAC
Marriott Vacations’s (NYSE:VAC) Q4 Sales Beat Estimates StockStory - Wed Feb 26, 4:40PM CST

Marriott Vacations’s (NYSE:VAC) Q4 Sales Beat Estimates

VAC : 52.36 (-0.83%)
VAC
Marriott Vacations (VAC) Q4 Earnings: What To Expect StockStory - Tue Feb 25, 7:09AM CST

Marriott Vacations (VAC) Q4 Earnings: What To Expect

CHH : 120.55 (-0.21%)
SABR : 2.03 (+1.00%)
VAC : 52.36 (-0.83%)
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer PR Newswire - Tue Sep 26, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases PR Newswire - Mon Aug 28, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q2 Earnings Snapshot AP - Fri Aug 11, 2023

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q1 Earnings Snapshot AP - Thu May 11, 2023

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 PR Newswire - Thu Apr 20, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Author
Promising Upsides on these Biotech Penny Stocks MarketBeat - Tue Apr 18, 2023

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

GMDA : 0.0327 (-18.25%)
VTVT : 19.32 (-1.78%)
SABS : 1.4100 (-1.12%)
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer PR Newswire - Tue Sep 26, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases PR Newswire - Mon Aug 28, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q2 Earnings Snapshot AP - Fri Aug 11, 2023

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q1 Earnings Snapshot AP - Thu May 11, 2023

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 PR Newswire - Thu Apr 20, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Author
Promising Upsides on these Biotech Penny Stocks MarketBeat - Tue Apr 18, 2023

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

GMDA : 0.0327 (-18.25%)
VTVT : 19.32 (-1.78%)
SABS : 1.4100 (-1.12%)
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer PR Newswire - Tue Sep 26, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases PR Newswire - Mon Aug 28, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q2 Earnings Snapshot AP - Fri Aug 11, 2023

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
VTv Therapeutics: Q1 Earnings Snapshot AP - Thu May 11, 2023

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 19.32 (-1.78%)
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 PR Newswire - Thu Apr 20, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 19.32 (-1.78%)
Author
Promising Upsides on these Biotech Penny Stocks MarketBeat - Tue Apr 18, 2023

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

GMDA : 0.0327 (-18.25%)
VTVT : 19.32 (-1.78%)
SABS : 1.4100 (-1.12%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Marriott Vacations Worldwide Corporation is a vacation company which offers vacation ownership, exchange, rental and resort and property management along with related businesses, products and services. Marriott Vacations Worldwide Corporation is based in ORLANDO, Fla.

See More

VAC Related ETFs

Managed Assets
Percent
Symbol %Holdings 3M %Chg
VAC -38.58%
Marriot Vacations Worldwide Cor
ESGV 1% -15.89%
ESG U.S. Stock Vanguard ETF
IJH 0.07% -16.89%
S&P Midcap 400 Ishares Core ETF
VB 0.05% -18.14%
Smallcap ETF Vanguard
VBR 0.08% -16.39%
Smallcap Value ETF Vanguard
VTI 0.01% -14.65%
Total Stock Market ETF Vanguard
Symbol %Holdings 3M %Chg
VAC -38.58%
Marriot Vacations Worldwide Cor
FXD 1.01% -18.37%
Consumer Disc Alphadex ETF FT
CSB 0.6% -14.11%
Victory US Smallcap HI Div Vol Wtd ETF
FYT 0.59% -19.26%
Smallcap Value Alphadex Fund FT
RFV 0.5% -17.79%
S&P Midcap 400 Pure Value Invesco ETF
NIXT 0.44% -20.02%
Research Affiliates Deletions ETF

VAC Related stocks

Symbol Last 3M %Chg
VAC 52.36 -38.58%
Marriot Vacations Worldwide Cor
ABNB 113.63 -14.33%
Airbnb Inc Cl A
RCL 195.60 -17.64%
Royal Caribbean Cruises Ltd
TCOM 56.77 -15.19%
Trip.com Group Ltd ADR
CCL 17.54 -30.42%
Carnival Corp
PLNT 94.38 -11.35%
Planet Fitness

Compare Symbols

Key Turning Points

Daily
52-Week
3rd Resistance Point 54.29
2nd Resistance Point 53.75
1st Resistance Point 53.27
Last Price 52.36
1st Support Level 52.25
2nd Support Level 51.71
3rd Support Level 51.23

See More

52-Week High 103.51
Fibonacci 61.8% 82.77
Fibonacci 50% 76.37
Fibonacci 38.2% 69.96
Last Price 52.36
52-Week Low 49.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro
Wed, Apr 23, 2025 5:00 PM UTC
Reserve Your Spot

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.

Start 30-Day Risk Free Trial